Hims & Hers Health Sees Unusually High Options Volume (NYSE:HIMS)

Hims & Hers Health, Inc. (NYSE:HIMS) saw unusually large options trading activity on Wednesday. Traders bought 322,282 call options on the stock. This is an increase of approximately 128% compared to the average volume of 141,619 call options.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Strategic partnership with Novo Nordisk lifts growth narrative — the alliance to expand access to weight‑loss drugs via HIMS’ platform has driven intraday rallies and renewed investor interest in HIMS’ addressable market and platform monetization potential. Hims & Hers Stock Jumps After Novo Nordisk Deal. What It Means for Drugmaker
• Positive Sentiment: Broker upgrades and price targets buoy sentiment — Barclays and other brokers have raised outlooks or forecasts for HIMS, calling for strong price appreciation and citing the Novo tie‑up and platform growth as catalysts. Those notes coincide with elevated volume and helped earlier upside. Barclays Forecasts Strong Price Appreciation for Hims & Hers Health (NYSE:HIMS) Stock
• Positive Sentiment: Analyst upgrades and heavy intraday buying — Bank of America and Deutsche Bank coverage changes and related media reports triggered heavy volume and a premarket rally as high as ~7%, showing event‑driven buying interest. Hims & Hers Health (NYSE:HIMS) Raised to Neutral at Bank of America
• Neutral Sentiment: Corporate hires and PR changes — HIMS added a communications leader as it navigates the Novo story and broader reputation/legal issues; important for messaging but not an immediate earnings driver. Hims & Hers Adds Communications Leader As Expansion And Novo Story Evolve
• Neutral Sentiment: Market commentary highlights HIMS as a headline name in weekly reviews — broader market context (inflation, Fed) remains dominant for sentiment versus company‑specific fundamentals. MarketBeat Week in Review – HIMS/Novo Mention
• Negative Sentiment: Regulatory, legal and margin overhangs remain significant — coverage notes and deep dives cite FDA scrutiny of compounded GLP‑1 products, potential DOJ interest, and a patent suit from Novo previously; these risks help explain the multi‑week/month share decline. Is Hims & Hers Really the Growth Stock to Buy That It Appears?
• Negative Sentiment: Recent price weakness and analyst notes — outlets flagged a ~29% decline over three months and intraday drops larger than the broader market, driven by margin pressure and investor concern that growth may be more volatile than expected. Hims & Hers Plunges 29.4% in Three Months: How to Play the Stock?
• Negative Sentiment: Short‑term sell pressure visible in trading — coverage from Zacks and others notes the stock fell more than the market on headlines, suggesting newsflow and risk appetite are driving near‑term volatility. Here’s Why Hims & Hers Health, Inc. (HIMS) Fell More Than Broader Market

Insider Activity at Hims & Hers Health

In other news, COO Michael Chi sold 13,750 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $36.71, for a total transaction of $504,762.50. Following the completion of the sale, the chief operating officer owned 305,161 shares of the company’s stock, valued at approximately $11,202,460.31. The trade was a 4.31% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Oluyemi Okupe sold 9,067 shares of the business’s stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $30.34, for a total value of $275,092.78. Following the completion of the sale, the chief financial officer owned 91,617 shares of the company’s stock, valued at $2,779,659.78. The trade was a 9.01% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 80,463 shares of company stock worth $2,846,696 over the last ninety days. 13.71% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Hims & Hers Health

Large investors have recently made changes to their positions in the business. Virtus Advisers LLC acquired a new stake in shares of Hims & Hers Health in the 2nd quarter worth $26,000. Quent Capital LLC acquired a new stake in Hims & Hers Health in the third quarter worth about $28,000. Flagship Harbor Advisors LLC purchased a new stake in shares of Hims & Hers Health during the fourth quarter worth about $28,000. Binnacle Investments Inc purchased a new stake in shares of Hims & Hers Health during the third quarter worth about $28,000. Finally, Bogart Wealth LLC increased its holdings in shares of Hims & Hers Health by 235.8% during the fourth quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Hims & Hers Health Stock Down 0.9%

HIMS stock traded down $0.21 during trading on Friday, reaching $23.63. 31,358,210 shares of the company traded hands, compared to its average volume of 35,371,910. The business has a 50 day simple moving average of $24.01 and a 200 day simple moving average of $37.57. Hims & Hers Health has a 12 month low of $13.74 and a 12 month high of $70.43. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.70 and a current ratio of 1.90. The company has a market capitalization of $5.39 billion, a price-to-earnings ratio of 46.34, a price-to-earnings-growth ratio of 2.45 and a beta of 2.55.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, February 23rd. The company reported $0.08 EPS for the quarter, topping analysts’ consensus estimates of $0.02 by $0.06. Hims & Hers Health had a net margin of 5.47% and a return on equity of 22.48%. The business had revenue of $617.82 million during the quarter, compared to the consensus estimate of $619.48 million. During the same period in the previous year, the company posted $0.11 earnings per share. The firm’s revenue was up 28.4% on a year-over-year basis. On average, equities research analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its board has approved a share buyback plan on Monday, November 17th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the company to reacquire up to 3% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s leadership believes its stock is undervalued.

Wall Street Analyst Weigh In

A number of equities analysts have recently issued reports on HIMS shares. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $25.00 to $28.00 and gave the stock a “hold” rating in a research report on Tuesday. Evercore set a $24.00 price objective on shares of Hims & Hers Health in a research note on Tuesday, February 24th. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Wednesday, February 25th. Morgan Stanley reduced their price target on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a report on Tuesday, February 24th. Finally, Barclays upped their price target on shares of Hims & Hers Health from $25.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday. Three analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $30.75.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.